Edico Genome's DRAGEN™ Bio-IT Processor Enhances PerkinElmer's Next-Generation Sequencing Workflow

Edico Genome's DRAGEN™ Bio-IT Processor Enhances PerkinElmer's Next-Generation Sequencing Workflow

Processor Accelerates Analysis Times by 60 Fold for Whole Genome and Whole Exome Sequencing, Maintains Greater than 99 Percent Sensitivity

SAN DIEGO, May 6, 2015 /PRNewswire/ -- Edico Genome today announced that PerkinElmer, Inc. has purchased a DRAGEN™ Bio-IT processor to expedite the analysis of its customers' next-generation sequencing (NGS) data. Applying the processor to PerkinElmer's NGS workflow, DRAGEN accelerates analysis time for whole genome and whole exome sequencing 60 fold, compared to standard industry software, while maintaining greater than 99 percent sensitivity. The processor will be integrated into PerkinElmer's CLIA-certified, high-throughput sequencing facility.

"As the applications of NGS grow, our customers can significantly benefit from a solution that is able to rapidly analyze the big data generated by NGS to support critical research, biotechnology and drug development applications," said Edward Szekeres, Jr., Ph.D., Director of Software Development, PerkinElmer. "DRAGEN's ability to analyze NGS data quickly and still maintain accuracy was the logical solution to integrate into our NGS workflow, enabling our customers to gain valuable insights as quickly as technology allows."

Added Pieter van Rooyen, Ph.D., Chief Executive Officer of Edico Genome, "PerkinElmer is a global company that has always been dedicated to offering its customers, including scientists, clinicians and lab professionals, cutting-edge and innovative tools to streamline their research. We look forward to working with PerkinElmer to enable their NGS customers around the world to access the benefits of DRAGEN and derive insights from their results as quickly and effectively as possible."

DRAGEN, the world's first NGS Bio-IT processor, is a reconfigurable platform designed to massively accelerate secondary analysis of NGS while simultaneously improving accuracy, removing a key bottleneck in NGS workflow. DRAGEN is loaded with highly optimized algorithms for mapping, alignment, sorting and variant calling, and the flexible platform can be loaded with additional algorithms for a range of secondary analysis pipelines, such as whole genome or exome, RNAseq, methylome, microbiome and cancer. The solution can be integrated directly into NGS bioinformatics servers and sequencing instruments and is provided with accompanying software as a Platform-as-a-Service (PaaS). Interested parties may inquire about DRAGEN at http://www.edicogenome.com/dragen/get-dragen-now/.

About Edico Genome
Edico Genome, developer of the world's first next-generation sequencing Bio-IT processor, DRAGEN™, is helping usher in the new era of precision medicine by enabling customized treatments and data-driven insights tailored to the individual. At the heart of personalized medicine is next-generation sequencing (NGS), which is growing at an unprecedented pace. By increasing the speed and accuracy of NGS data analysis, such as whole genome sequencing, Edico Genome's computing platform makes it easier to discover links between DNA sequence variations and human disease, allowing clinicians and researchers to reveal answers more quickly. For more information, visit www.EdicoGenome.com and follow #DRAGENonFIRE.

Logo - http://photos.prnewswire.com/prnh/20140716/127788

SOURCE Edico Genome



Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.